Table 3.
Therapies and Outcome Measures of the COVID-19 Patients
| Variables | Total n=79 | Pediatric Ward n=58 (73.4%) | PICU n=21(26.6%) | P value |
|---|---|---|---|---|
| Pain and fever management, No (%) | ||||
| Paracetamol | 58/66 (88%) | 37/45 (82%) | 21 (100%) | 0.038* |
| Ibuprofen | 34/54 (63%) | 25/37 (68%) | 9/17 (53%) | 0.231 |
| Hydroxychloroquine | 47/65 (72%) | 32/45 (71%) | 15/20 (75%) | 0.498 |
| Oseltamivir | 3/79 (4%) | 3/58 (5.2%) | 0 (100) | 0.390 |
| Systemic steroid | 27/78 (35%) | 14/57 (25%) | 13/21 (62%) | 0.003* |
| Favipiravin | 7/79 (9%) | 1/58 (2%) | 6/21 (29%) | <0.001* |
| Broad-spectrum antibiotics, No (%) | ||||
| Ceftriaxone | 25/78 (32%) | 12/57 (21%) | 13/21 (62%) | 0.001* |
| Azithromycin | 36/53 (68%) | 26/36 (72%) | 10/17 (59%) | 0.252 |
| Cefuroxime | 33/54 (61%) | 27/36 (75%) | 6/18(33%) | 0.004* |
| Ampicillin and Gentamycin | 10/79 (13%) | 8/58 (14%) | 2/21 (10%) | 0.471 |
| Tazocin | 12/79 (15%) | 5/58 (9%) | 7/21 (33%) | 0.012* |
| Other therapies | ||||
| Intravenous Immunoglobulin | 7/79 (9%) | 0 (0.00%) | 7/21 (33%) | <0.001* |
| Nebulizer bronchodilators | 31/79 (39%) | 16/58 (28%) | 15/21 (71%) | 0.001* |
| Outcome measures, No (%) | ||||
| Total hospital stays, median (IQR) | 6 (3–10) | 4.5 (3–7) | 10 (7.5–12) | <0.001* |
| Discharged, No (%) | 78/79 (98.7%) | 58/58 (100%) | 20/21 (95.2%) | 0.610 |
Note: *P < 0.05 (significant).